Prostate Cancer - Results from #28660

iProstate, a mathematical predictive model-based, 3D-rendering tool to visualize the location and extent of prostate cancer - Abstract February 10, 2011

Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.2 and confirmation of signal on 17q21-q22 - Abstract February 10, 2011

Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-Up Study - Abstract February 10, 2011

Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy - Abstract February 10, 2011

Associations of circulating and dietary vitamin D with prostate cancer risk: A systematic review and dose-response meta-analysis - Abstract February 10, 2011

Extending the indications and anatomical limits of pelvic lymph node dissection for prostate cancer: Improved staging or increased morbidity? - Abstract February 10, 2011

Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: Recommendations from a European Consensus Meeting - Abstract February 10, 2011

Sweeping view of prostate cancer genome yields deep insights February 10, 2011

When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? - Abstract February 9, 2011

Relationship between prostate-specific antigen and obesity in prostate cancer screening: Analysis of a large cohort in Japan - Abstract February 9, 2011

Exosomes as biomarker treasure chests for prostate cancer - Abstract February 9, 2011

Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy - Abstract February 9, 2011

Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer - Abstract February 9, 2011

PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: Impact on hemiablative focal therapy - Abstract February 9, 2011

Dutasteride not a cost-effective way to prevent prostate cancer in some February 9, 2011

Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study - Abstract February 8, 2011

Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid - Abstract February 8, 2011

5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression - Abstract February 8, 2011

Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer - Abstract February 8, 2011

Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers - Abstract February 8, 2011

Page 1434 of 1437